PMID: 11904315Mar 21, 2002Paper

Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy

Journal of the National Cancer Institute
Arnold L PotoskyJanet L Stanford

Abstract

Many men diagnosed with clinically localized prostate cancer are initially treated conservatively, receiving neither surgery nor radiotherapy for the first year. Treatment patterns and quality-of-life outcomes have not been previously reported for a population-based sample of such men. A population-based random sample of men (n = 661) from six geographic regions who had been newly diagnosed with clinically localized prostate cancer from 1994 through 1995 were followed for up to 1 year. Eligible subjects received neither surgery nor radiotherapy within 1 year of initial diagnosis. We assessed disease-specific and generic quality-of-life outcomes in men receiving androgen deprivation therapy (ADT) compared with men receiving no therapy. All statistical tests were two-sided. Two hundred and forty-five study patients received ADT and the remaining 416 patients received no therapy. Approximately two thirds of the patients (n = 159) receiving ADT had either baseline Gleason scores greater than six or serum prostate-specific antigen values above 20 ng/mL. Among men who were sexually potent before diagnosis (ADT = 88 patients; no therapy = 223 patients), 80% of those on ADT reported being impotent after 1 year compared with 30% of thos...Continue Reading

Citations

Jul 10, 2008·JAMA : the Journal of the American Medical Association·Grace L Lu-YaoSiu-Long Yao
Jun 11, 2008·Cancer Causes & Control : CCC·Michael GoodmanJack Mandel
Sep 25, 2009·Cancer Causes & Control : CCC·Young Kyung DoPaul A Godley
Jun 8, 2007·Journal of General Internal Medicine·Richard M HoffmanAnn S Hamilton
Apr 7, 2004·Current Oncology Reports·Allen C Chen, Daniel P Petrylak
May 21, 2003·Current Urology Reports·David F Penson, Mark S Litwin
May 5, 2005·Current Urology Reports·Allen C Chen, Daniel P Petrylak
May 15, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Francesc CasasAlmudena Zapatero
Jul 10, 2012·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·M RouprêtF Desgrandchamps
Jan 11, 2012·Asian Journal of Andrology·Clarisse R Mazzola, John P Mulhall
Nov 28, 2008·International Journal of Impotence Research·B B Yeap
Feb 24, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T BessedeB Escudier
Oct 19, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D J StoreyM Sharpe
Dec 7, 2010·Journal of the National Cancer Institute·Nancy L Keating
May 23, 2006·Journal of Clinical Pathology·W S A SmellieP J Carey
May 22, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrew J StephensonAlan Pollack
Mar 25, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luis SouhamiHoward Sandler
Jul 1, 2010·Patient Related Outcome Measures·Jin-Shei LaiDavid Cella
Aug 13, 2009·Indian Journal of Urology : IJU : Journal of the Urological Society of India·Aditya BagrodiaIthaar H Derweesh
Nov 19, 2013·Journal of Comparative Effectiveness Research·Richard M HoffmanMichael J Barry
May 30, 2014·Endocrine-related Cancer·Carolyn A AllanKati L Matthiesson
Apr 6, 2004·Journal of General Internal Medicine·Robert J VolkMurray D Krahn
Jan 1, 2014·Sexual Medicine Reviews·Mikkel Fode, Jens Sønksen
Dec 18, 2013·Current Problems in Cancer·Veronica Sanchez VarelaSharon L Bober
Oct 22, 2013·Urology·Matthew J Resnick
Jul 16, 2010·The Journal of Sexual Medicine·Stacy ElliottUNKNOWN ADT Survivorship Working Group
Sep 24, 2015·Clinical Genitourinary Cancer·Giuseppe CollocaFranco Checcaglini
Feb 4, 2010·Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie·P Mongiat-ArtusUNKNOWN Membres du CCAFU
Oct 28, 2008·Critical Reviews in Oncology/hematology·Supriya G MohileWilliam Dale
Jun 10, 2008·International Journal of Radiation Oncology, Biology, Physics·Floortje MolsLonneke V van de Poll-Franse

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.